ArticleThe pharmacogenomics journal2013
The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia.
Article in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Effects of game-based physical education program on enjoyment in children and adolescents: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review.Pharmacotherapy · 2020Pooled it
- Article
- Elucidating the Complex Etiology of Schizophrenia: Comprehensive Insights into the Therapeutic Roles of Natural Compounds and Pharmacological Interventions.Current pharmaceutical design · 2026Review
- DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study.Clinical epigenetics · 2024Observational
- Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Altered DNA methylation of CYP2E1 gene in schizophrenia patients with tardive dyskinesia.BMC medical genomics · 2022Article
- Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia.International journal of genomics · 2018Article
- Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders.Clinical epigenetics · 2017Review
- Making Sense of Epigenetics.The international journal of neuropsychopharmacology · 2016Review
- Epigenetic mechanisms in schizophrenia.Progress in biophysics and molecular biology · 2015Review
- Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children.The pharmacogenomics journal · 2015Article
- The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects.NPJ schizophrenia · 2015Article
- DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder.Epigenomics · 2015Article
- Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed.Current psychiatry reports · 2014Review
- Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.Psychopharmacology · 2014Article
- Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults.JAMA psychiatry · 2014Article
- Exercise: putting action into our epigenome.Sports medicine (Auckland, N.Z.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The catechol-O-methyl transferase (COMT) 158Val/Met variant has been suggested to play a role in COMT function. Epigenetic regulation of COMT may further influence the prevalence of metabolic syndrome in these patient populations. This study examined the correlation between COMT promoter methylation and metabolic syndrome in schizophrenia patients receiving atypical antipsychotic (AAP) therapy. DNA was extracted from peripheral blood samples of schizophrenia subjects screened for metabolic syndrome. Pyrosequencing was used to analyze two methylation sites of the soluble COMT (COMT-s) promoter region. Associations between AAP use, lifestyle variables, metabolic syndrome and COMT genotype with peak methylation values were analyzed. Data are reported in 85 subjects. Methylation on CpG site 1 had a mean of 79.08% (±4.71) and it was 12.43% (±1.19) on site 2. COMT genotype proved to be an indicator of COMT methylation status on site 1 (F(2, 84)=5.78, P=0.0044) and site 2 (F(2, 84),=3.79, P=0.027). A significant negative correlation between physical activity and COMT promoter region methylation was found in Val/Val homozygous patients (site 1: P=0.013 and site 2: P=0.019). Those homozygous for Met/Met showed a positive correlation between promoter site methylation and physical activity (site 1: P=0.027, site 2: P=0.005), and between CpG site methylation and metabolic syndrome (site 1: P=0.002; site 2: P=0.001). The results of this study suggest that COMT promoter region methylation is largely influenced by COMT genotype and that physical activity plays a significant role in epigenetic modulation of COMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.